


PCRopsis™ Reagent SRVD Mediates Direct PCR From Saliva

MIAMI, FLORIDA, U.S.A., April 16, 2021 /EINPresswire.com/ -- [PCRopsis™ Reagent SRVD](#) was recently shown to mediate direct PCR amplification from viral, bacterial and mammalian targets from human saliva.

Reagent SRVD offers the PCR testing industry a robust, reliable, and cost-effective alternative to traditional RNA and DNA extraction for downstream PCR applications. You simply mix 1 volume of saliva with 1 volume of Reagent SRVD, heat at 95°C for 10 minutes, and then you use the processed sample directly into your PCR mixture.

Reagent SRVD can be combined with PCRopsis™ [RVD Enhancer](#) for added compatibility with diverse saliva transport mediums and complex pure saliva specimens (e.g., heavily contaminated saliva). Moreover, this combination offers extra cost saving per test, is highly compatible with automation, and has been shown to outperform competing direct PCR technologies on the market.



“

We are listening to our customers. The release of Reagent SRVD for direct PCR applications from saliva is testament to that promise.”

Abhignyan Nagesetti, Ph.D.

“Our goal is to provide market leading direct PCR solutions to users of PCR technologies. The launch of Reagent SRVD expands our offering to saliva, a key diagnostic bio-fluid.”, said Obdulio Piloto, Ph.D., C.E.O. at Entopsis, Inc.

“We are listening to our customers. The release of Reagent SRVD for direct PCR applications from saliva is testament to that promise.” said Abhignyan Nagesetti, Ph.D., Head of

Manufacturing at Entopsis, Inc.

About Entopsis / PCRopsis

Entopsis was founded in 2011 to pursue the simple idea that an unbiased approach to diagnostics using bio-molecular profiles can be clinically and scientifically useful. The company is predominantly focused in the areas of oncology and infectious diseases, and exploring new areas lacking accurate diagnostics. PCRopsis™ technologies are based on Entopsis' core platform, OpsiDx™, and aims to streamline research and clinical applications, while decreasing costs. For more information, please visit www.Entopsis.com and www.PCRopsis.com

Obdulio Piloto

Entopsis

+1 888-407-5070

info@entopsis.com

This press release can be viewed online at: <https://www.einpresswire.com/article/538714959>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.